Fig. 3From: Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective studyThe platelet count (a, b) and splenic volume (c, d) in patients with chronic HCV infection. Patients who achieved an SVR with antiviral treatment (a, c) (n = 7). Patients who did not achieve an SVR (b, d) (n = 8). p < 0.05, n.s not significant. SVR, sustained virologic responseBack to article page